Antidotes are specific pharmacological agents that counteract the effects of poisons through defined mechanisms, representing a targeted therapeutic approach that complements general supportive and decontamination measures in the management of poisoning. While only a small fraction of poisoned patients receive a specific antidote, the timely administration of the appropriate antidote can be life-saving. Antidotes act through several distinct mechanisms, including receptor antagonism, chemical neutralization, metabolic modulation, and enhancement of elimination.
Naloxone is a competitive antagonist at mu, kappa, and delta opioid receptors with a high affinity for the mu receptor responsible for opioid-induced respiratory depression and analgesia. It reverses opioid effects within one to two minutes of intravenous administration. The standard initial dose is 0.04 to 0.4 mg intravenously, titrated to effect, though higher doses may be required for synthetic opioids such as fentanyl. Naloxone has a shorter half-life than most opioids, and repeated doses or continuous infusion may be necessary to prevent recurrence of respiratory depression after initial reversal. Intranasal and intramuscular formulations are available for administration by first responders and laypersons in community settings.
Flumazenil is a competitive antagonist at the benzodiazepine binding site of the GABA-A receptor, reversing the sedative and respiratory depressant effects of benzodiazepines. However, flumazenil use is controversial because it can precipitate acute withdrawal seizures in benzodiazepine-dependent patients and cause arrhythmias in patients with coexisting tricyclic antidepressant overdose. It is contraindicated in patients with a history of seizure disorders, chronic benzodiazepine use, or suspected co-ingestion of proconvulsant drugs. When used, flumazenil should be administered in small incremental doses of 0.1 to 0.2 mg rather than as a bolus.
N-Acetylcysteine (NAC) is the specific antidote for paracetamol (acetaminophen) poisoning and acts through multiple mechanisms. Its primary mechanism is replenishment of hepatic glutathione stores, which are depleted by the toxic metabolite NAPQI. NAC also directly reduces NAPQI, improves hepatic oxygen delivery, and has anti-inflammatory and antioxidant effects. NAC is most effective when administered within eight to ten hours of paracetamol ingestion, after which efficacy declines but remains beneficial even in late-presenting patients. The standard regimen involves a loading dose followed by maintenance infusions over 20 to 72 hours, depending on the protocol used and the clinical response.
Fomepizole is a competitive inhibitor of alcohol dehydrogenase, the enzyme responsible for the initial metabolism of methanol and ethylene glycol to their toxic metabolites. By blocking this first metabolic step, fomepizole prevents the formation of formic acid (from methanol) and glycolic and oxalic acids (from ethylene glycol), which cause metabolic acidosis, visual toxicity, and renal failure. Fomepizole has largely replaced ethanol infusion as the preferred therapy for these poisonings because of its predictable pharmacokinetics, favorable safety profile, and ease of dosing without the need for blood alcohol concentration monitoring.
Digoxin immune Fab (Digibind) consists of antibody fragments that bind digoxin and digitoxin with high affinity, forming inactive complexes that are eliminated by the kidneys. It is indicated for life-threatening digoxin toxicity, including hemodynamically significant arrhythmias, hyperkalemia, and massive overdose. Clinical improvement typically occurs within 30 to 60 minutes of administration. Dosing is based on the ingested dose or steady-state serum digoxin concentration. Rebound toxicity can occur in patients with renal impairment as the antibody-toxin complexes dissociate over time.
Physostigmine is a reversible acetylcholinesterase inhibitor that increases acetylcholine concentrations at central and peripheral synapses, counteracting the anticholinergic effects of drugs such as atropine, diphenhydramine, and tricyclic antidepressants. It is indicated specifically for anticholinergic delirium but should be used with caution due to the risk of bradycardia, seizures, and bronchospasm. Physostigmine is contraindicated in patients with conduction abnormalities, asthma, or suspected overdose of drugs that slow cardiac conduction.
Limitations of antidotal therapy include the requirement for early administration, the potential for adverse effects, the limited availability of certain antidotes, and the fact that antidotes address only specific toxic effects rather than reversing all consequences of poisoning. Antidotes should never replace comprehensive supportive care, and their use must be guided by careful assessment of the risks and benefits in each case. Regional poison control centers maintain inventories of rarely used antidotes and can facilitate their procurement in emergency situations.
